Real-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: a prospective study.

BACKGROUND AND AIMS: Recent randomised controlled trials have demonstrated the efficacy of tirzepatide in inducing weight loss among adults with overweight or obesity, irrespective of diabetes mellitus status. However, evidence from real-world settings remains limited. This study aimed to evaluate the effectiveness and safety of tirzepatide for weight management in routine clinical practice. METHODS: and at least one weight-related comorbidity in real-world conditions. The primary outcomes were changes in body weight and body composition after 6 months of treatment. Secondary assessments included anthropometric and cardiometabolic parameters, quality of life, and tolerability. RESULTS: The median tirzepatide dose at 6 months was 7.5 mg. At this visit, the mean body weight reduction was 18.04 kg, representing a 17.21% decrease from baseline. A total of 95.35% of participants achieved at least 5% weight loss, and 60.47% achieved ≥15%. Significant improvements were observed in glycaemic and lipid profiles, with enhancements in health-related quality of life and a favourable tolerability profile. The dropout rate was 3.7%. CONCLUSIONS: This prospective real-world study confirms the effectiveness and safety of tirzepatide for weight management, even at maintenance doses lower than the approved dose, and supports findings from randomised clinical trials.